EphrinB-mediated reverse signalling controls junctional integrity and pro-inflammatory differentiation of endothelial cells

Summary

The EphB/ephrinB receptor-ligand system is pivotal for the development of the embryonic vasculature and for angiogenesis in the adult organism. We observed that (i) the expression of ephrinB2 and ephrinB1 is up-regulated in capillaries during inflammation, that (ii) these ligands are localised on the luminal endothelial surface, and that (iii) they interact with the ephrinB-receptor EphB2 on monocyte/macrophages. This study delineates the impact of ephrinB-mediated reverse signalling on the integrity and proinflammatory differentiation of the endothelium. To this end, in vitro analyses with human cultured endothelial cells reveal that knockdown of ephrinB2 or ephrinB1 impairs monocyte transmigration through the endothelium. While ephrinB2 but not ephrinB1 interacts with PECAM-1 (CD31) in this context, reverse signalling by ephrinB1 but not ephrinB2 elicits a c-Jun N-terminal kinase (JNK)-dependent up-regulation of E-selectin expression. Furthermore, treatment of endothelial cells with soluble EphB2 receptor bodies or EphB2-overexpressing mouse myeloma cells links ephrinB2 to PECAM-1 and induces its Src-dependent phosphorylation while diminishing Src homology phosphotyrosyl phosphatase-2 (SHP-2) activity and increasing endothelial cell permeability. We conclude that extravasation of EphB2 positive leukocyte populations is facilitated by lowering the integrity of endothelial cell junctions and enhancing the pro-inflammatory phenotype of the endothelium through activation of ephrinB ligands.

Keywords

Inflammation - ephrinB1 - ephrinB2 - EphB2 - monocytes - endothelial cells

• References

• 1 Schnoor M, Parkos CA. Disassembly of endothelial and epithelial junctions during leukocyte transmigration. Front Biosci 2008; 13: 6638-6652.
• 2 Engelhardt B, Wolburg H. Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house?. Eur J Immunol 2004; 34: 2955-2963.
• 3 Augustin HG, Reiss Y. EphB receptors and ephrinB ligands: regulators of vascular assembly and homeostasis. Cell Tissue Res 2003; 314: 25-31.
• 4 Zhang J, Hughes S. Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 2006; 208: 453-461.
• 5 Coulthard MG, Morgan M, Woodruff TM. et al. Eph/Ephrin signaling in injury and inflammation. Am J Pathol 2012; 181: 1493-1503.
• 6 Korff T, Braun J, Pfaff D. et al. Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment. Blood 2008; 112: 73-81.
• 7 Korff T, Dandekar G, Pfaff D. et al. Endothelial ephrinB2 is controlled by microenvironmental determinants and associates context-dependently with CD31. Arterioscler Thromb Vasc Biol 2006; 26: 468-474.
• 8 Yu G, Luo H, Wu Y. et al. Ephrin B2 induces T cell costimulation. J Immunol 2003; 171: 106-114.
• 9 Fuller T, Korff T, Kilian A. et al. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci 2003; 116: 2461-2470.
• 10 Pfaff D, Heroult M, Riedel M. et al. Involvement of endothelial ephrin-B2 in adhesion and transmigration of EphB-receptor-expressing monocytes. J Cell Sci 2008; 121: 3842-3850.
• 11 Braun J, Hoffmann SC, Feldner A. et al. Endothelial cell ephrinB2-dependent activation of monocytes in arteriosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 297-305.
• 12 Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002; 03: 475-486.
• 13 Luo H, Yu G, Wu Y. et al. EphB6 crosslinking results in costimulation of T cells. J Clin Invest 2002; 110: 1141-1150.
• 14 Luo H, Yu G, Tremblay J. et al. EphB6-null mutation results in compromised T cell function. J Clin Invest 2004; 114: 1762-1773.
• 15 Luo H, Wu Z, Qi S. et al. Ephrinb1 and Ephrinb2 are associated with interleukin-7 receptor alpha and retard its internalisation from the cell surface. J Biol Chem 2011; 286: 44976-44987.
• 16 Pasquale EB. Ephephrin bidirectional signaling in physiology and disease. Cell 2008; 133: 38-52.
• 17 Rohnelt RK, Hoch G, Reiss Y. et al. Immunosurveillance modelled in vitro: naive and memory T cells spontaneously migrate across unstimulated microvascular endothelium. Int Immunol 1997; 09: 435-450.
• 18 Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873-887.
• 19 Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003; 24: 327-334.
• 20 Rattan V, Sultana C, Shen Y. et al. Oxidant stress-induced transendothelial migration of monocytes is linked to phosphorylation of PECAM-1. Am J Physiol 1997; 273: E453-461.
• 21 Rattan V, Shen Y, Sultana C. et al. Glucose-induced transmigration of mono-cytes is linked to phosphorylation of PECAM-1 in cultured endothelial cells. Am J Physiol 1996; 271: E711-717.
• 22 Liu G, Place AT, Chen Z. et al. ICAM-1-activated Src and eNOS signaling increase endothelial cell surface PECAM-1 adhesivity and neutrophil transmigration. Blood 2012; 120: 1942-1952.
• 23 Navarro P, Ruco L, Dejana E. Differential localisation of VE- and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localisation. J Cell Biol 1998; 140: 1475-1484.
• 24 Stel HV, Sakariassen KS, de Groot PG. et al. Von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985; 65: 85-90.
• 25 Projahn D, Koenen RR. Platelets: key players in vascular inflammation. J Leukoc Biol 2012; 92: 1167-1175.
• 26 van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009; 85: 195-204.
• 27 Migliaccio G, Migliaccio AR, Adamson JW. In vitro differentiation of human granulocyte/macrophage and erythroid progenitors: comparative analysis of the influence of recombinant human erythropoietin, G-CSF, GM-CSF, and IL-3 in serum-supplemented and serum-deprived cultures. Blood 1988; 72: 248-256.
• 28 Xu Z, Lai KO, Zhou HM. et al. Ephrin-B1 reverse signaling activates JNK through a novel mechanism that is independent of tyrosine phosphorylation. J Biol Chem 2003; 278: 24767-24775.
• 29 Read MA, Whitley MZ, Gupta S. et al. Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 1997; 272: 2753-2761.
• 30 Tai LM, Holloway KA, Male DK. et al. Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 2010; 14: 1101-1112.
• 31 Wu JC, Yan HC, Chen WT. et al. JNK signaling pathway is required for bFGF-mediated surface cadherin downregulation on HUVEC. Exp Cell Res 2008; 314: 421-429.
• 32 Jackson JR, Seed MP, Kircher CH. et al. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457-465.
• 33 Kertesz N, Krasnoperov V, Reddy R. et al. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 2006; 107: 2330-2338.
• 34 Abengozar MA, de Frutos S, Ferreiro S. et al. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 2012; 119: 4565-4576.
• 35 Korff T, Aufgebauer K, Hecker M. Cyclic stretch controls the expression of CD40 in endothelial cells by changing their transforming growth factor-beta1 response. Circulation 2007; 116: 2288-2297.
• 36 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 37 Adams RH, Wilkinson GA, Weiss C. et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999; 13: 295-306.
• 38 Kojima T, Chang JH, Azar DT. Proangiogenic role of ephrinB1/EphB1 in basic fibroblast growth factor-induced corneal angiogenesis. Am J Pathol 2007; 170: 764-773.
• 39 Sakamoto A, Ishibashi-Ueda H, Sugamoto Y. et al. Expression and function of ephrin-B1 and its cognate receptor EphB2 in human atherosclerosis: from an aspect of chemotaxis. Clin Sci 2008; 114: 643-650.
• 40 Ilan N, Madri JA. PECAM-1: old friend, new partners. Curr Opin Cell Biol 2003; 15: 515-524.
• 41 Newman PJ, Newman DK. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol 2003; 23: 953-964.
• 42 Muller WA, Weigl SA, Deng X. et al. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993; 178: 449-460.
• 43 Duncan GS, Andrew DP, Takimoto H. et al. Genetic evidence for functional redundancy of Platelet/Endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions. J Immunol 1999; 162: 3022-3030.
• 44 Thompson RD, Noble KE, Larbi KY. et al. Platelet-endothelial cell adhesion molecule-1 (PECAM-1)-deficient mice demonstrate a transient and cytokine-specific role for PECAM-1 in leukocyte migration through the perivascular basement membrane. Blood 2001; 97: 1854-1860.
• 45 Newman DK, Hamilton C, Newman PJ. Inhibition of antigen-receptor signaling by Platelet Endothelial Cell Adhesion Molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56(lck). Blood 2001; 97: 2351-2357.
• 46 Henshall TL, Jones KL, Wilkinson R. et al. Src homology 2 domain-containing protein-tyrosine phosphatases, SHP-1 and SHP-2, are required for platelet endothelial cell adhesion molecule-1/CD31-mediated inhibitory signaling. J Immunol 2001; 166: 3098-3106.
• 47 Sagawa K, Kimura T, Swieter M. et al. The protein-tyrosine phosphatase SHP-2 associates with tyrosine-phosphorylated adhesion molecule PECAM-1 (CD31). J Biol Chem 1997; 272: 31086-31091.
• 48 Jackson DE, Ward CM, Wang R. et al. The protein-tyrosine phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-1 (PECAM-1) and forms a distinct signaling complex during platelet aggregation. Evidence for a mechanistic link between PECAM-1- and integrin-mediated cellular signaling. J Biol Chem 1997; 272: 6986-6993.
• 49 Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 2008; 121: 2115-2122.
• 50 Corada M, Liao F, Lindgren M. et al. Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood 2001; 97: 1679-1684.
• 51 Weis S, Shintani S, Weber A. et al. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004; 113: 885-894.
• 52 Paul R, Zhang ZG, Eliceiri BP. et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med 2001; 07: 222-227.